ClinicalTrials.gg
RecruitingNCT07579897Updated May 12, 2026

Group vs. Individual Metacognitive Therapy for Generalized Anxiety Disorder

An interventional study of Individual Metacognitive Therapy and Group Metacognitive Therapy in Generalized Anxiety Disorder, sponsored by Sorlandet Hospital HF. Recruiting at 2 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Sorlandet Hospital HF · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Generalized anxiety disorder (GAD) is a serious and long-lasting condition that can greatly reduce quality of life, work functioning, and use of health services. Metacognitive therapy (MCT) is an effective treatment for GAD, but it is not yet known whether individual MCT or group-based MCT provides the best results for patients.

This randomized controlled trial will compare two formats of MCT: individual treatment and group-based treatment (g-MCT). A total of 64 adults with GAD (32 in each treatment arm) will participate after providing informed consent. Participants will complete questionnaires, undergo clinical assessments, and allow the study to collect relevant health information from official registries.

The main aim of the study is to determine whether group-based MCT is non-inferior to individual MCT. A non-inferiority design tests whether the group format is not meaningfully less effective than the individual format. If group MCT is shown to have similar effects on anxiety symptoms and functioning, it could offer an efficient and resource-saving alternative in routine clinical care.

This will be the first study to systematically compare these two treatment formats in a real-world clinical setting. If group MCT proves to be as effective as individual therapy, it may help increase access to evidence-based treatment for people with GAD, reduce strain on mental health services, and support the development of more accessible and cost-effective care.

Read the detailed description

Generalized anxiety disorder (GAD) is a chronic and disabling condition characterized by persistent and uncontrollable worry. Individuals with GAD frequently experience reduced quality of life, impaired daily functioning, and elevated use of health care services. Although effective psychological treatments exist, including metacognitive therapy (MCT), it remains unclear which treatment delivery format provides the best balance of clinical effectiveness and efficient use of resources.

MCT is an evidence-based treatment targeting the metacognitive processes that maintain excessive worry, including beliefs about the usefulness and uncontrollability of worrying and the cognitive-attentional syndrome (CAS), a pattern of worry, rumination, threat monitoring, and unhelpful coping behaviors. Individual MCT has demonstrated strong and consistent effects across several clinical trials, while group-based MCT (g-MCT) has shown promising preliminary results. However, the two formats have never been directly compared in a randomized trial conducted in routine clinical care. This represents a meaningful gap in the research literature and limits the ability of services to make informed decisions about how to organize treatment.

This study addresses this gap by conducting a randomized controlled trial (RCT) comparing individual MCT with group-based MCT for adults with GAD. An RCT design is chosen because it provides the highest level of evidence for causal inference about treatment effects. A non-inferiority framework is used to test whether group MCT is not meaningfully less effective than individual MCT. This design is appropriate when an alternative treatment may offer practical advantages-such as lower cost, greater accessibility, or more efficient resource use-while aiming to demonstrate that clinical outcomes remain comparable.

A total of 64 adults with a primary diagnosis of GAD will be enrolled and randomized to either individual MCT or group MCT. Both interventions follow established MCT protocols and are delivered by trained clinicians. Treatment focuses on reducing worry, modifying maladaptive metacognitive beliefs, and promoting flexible attentional control. Data collection includes validated self-report questionnaires, structured clinical assessments, and-with participant consent-information obtained from official national registers to assess work participation and sick leave pre and post treatment.

Evaluating group-based MCT is particularly important in the context of mental health services, where demand often exceeds available treatment resources. If group MCT is found to be non-inferior to individual MCT, it could make it possible to offer effective therapy to more patients within the same amount of therapist time. This has the potential to reduce waiting times, improve access to evidence-based treatment, and support more sustainable use of clinical resources.

The findings from this trial will contribute to the evidence base for MCT, clarify which treatment format is most appropriate for adults with GAD, and inform clinical guidelines and service organization. As the first randomized study to directly compare individual and group MCT in a real-world clinical setting, the results may have meaningful implications for both clinical practice and mental health policy.

02

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Generalized Anxiety Disorder
  • GAD
  • Anxiety
  • Metacognitive Therapy
  • MCT
  • Group Metacognitive Therapy
  • Individual Metacognitive Therapy
  • Worry
  • Psychotherapy
  • RCT
  • Randomized Controlled Trial
  • Anxiety Treatment
  • Group Therapy
  • Adult Mental Health
  • Cognitive Attentional Syndrome
  • CAS
03

In context

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

This study's planned enrollment of 64 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.

Browse Generalized Anxiety Disorder studies →

Lead sponsor

Sorlandet Hospital HF is the lead sponsor of 75 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults with a primary diagnosis of generalized anxiety disorder (GAD). GAD-7 score ≥ 10 at screening/baseline. Participants must endorse that they experience problems with excessive worry

Exclusion criteria

Exclusion Criteria:

  1. Bipolar disorder;
  2. Psychosis;
  3. Ongoing substance abuse/dependence;
  4. Intellectual disability based on previous medical history;
  5. Eating disorder in need of medical attention;
  6. Unwillingness to refrain from anxiolytic drugs during the treatment;
  7. Current suicidal ideation with plan and intent;
  8. Taking an unstable dose of antidepressant, with recent dose-change within the last 4 weeks;
  9. Known cluster A or B personality disorder;
  10. Serious medical comorbidity (e.g.: cancer, severe renal failure)
  11. Language difficulties in need of an interpreter.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Active comparator
    Individual Metacognitive Therapy (MCT)

    Participants receive individual metacognitive therapy delivered by a trained clinician according to the established MCT protocol for generalized anxiety disorder. Treatment is provided weekly for 10 weeks, each session lasting approximately 45 minutes.

    Behavioral: Individual Metacognitive Therapy

  • Experimental
    Group Metacognitive Therapy (g-MCT)

    Participants receive group-based metacognitive therapy delivered by two trained clinicians according to the established group MCT protocol for generalized anxiety disorder. Treatment is delivered in small groups of 4-6 participants meeting weekly for 10 weeks. Each session lasts approximately 90 minutes.

    Behavioral: Group Metacognitive Therapy

Interventions

  • BehavioralIndividual Metacognitive Therapy

    Individual metacognitive therapy (MCT) is delivered by a trained clinician following the established protocol for generalized anxiety disorder. The treatment focuses on modifying maladaptive metacognitive beliefs, reducing the cognitive-attentional syndrome (CAS), and promoting flexible attentional control. Participants receive 10 weekly individual sessions, each lasting approximately 45 minutes. The intervention targets excessive worry, unhelpful coping strategies, and beliefs about the uncontrollability and danger of worry.

  • BehavioralGroup Metacognitive Therapy

    Group Metacognitive Therapy (g-MCT) is delivered by two trained clinicians following the established group MCT protocol for generalized anxiety disorder. Treatment is provided in small groups of 4-6 participants and focuses on modifying maladaptive metacognitive beliefs, reducing the cognitive-attentional syndrome (CAS), and improving attentional flexibility. Participants attend 10 weekly sessions, each lasting approximately 90 minutes.

06

What researchers measure

Primary outcomes

  1. Generalized Anxiety Disorder-7 (GAD-7)

    The Generalized Anxiety Disorder-7 (GAD-7) is a validated 7-item self-report measure assessing the severity of generalized anxiety symptoms over the past two weeks. Total scores range from 0 to 21, with higher scores indicating greater symptom severity. The primary outcome is change in GAD-7 score from pre-treatment (baseline, one week before treatment start) to post-treatment (one week after the last therapy session) and 3- month and 12- month follow up. The measure is widely used in clinical research and has demonstrated strong reliability, sensitivity to change, and clinical validity in GAD populations.

    Time frame: Pre-treatment (baseline; one week before treatment start) mid-treatment A (the day after therapy session 4), mid-treatment B (The day after therapy session 7), post-treatment (one week after the last therapy session), 3-month follow-up, 12-month follow-u

Secondary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    The Patient Health Questionnaire-9 (PHQ-9) is a 9-item validated self-report measure of depressive symptom severity over the past two weeks. Scores range from 0-27, with higher scores indicating more severe depressive symptoms.

    Time frame: Pre-treatment (baseline; one week before treatment start) mid-treatment A (the day after therapy session 4), mid-treatment B (The day after therapy session 7), post-treatment (one week after the last therapy sessio), 3-month follow-up, 12-month follow-up

  2. Generalized Anxiety Disorder Scale-Revised (GADS-R)

    The Generalized Anxiety Disorder Scale-Revised (GADS-R) is a self report questionaire assessing cognitive and behavioral symptoms of generalized anxiety disorder. The scale measures worry severety and maladaptive coping strategies on a 9-point Likert scale (0-8), while metacognitive beliefs about worry are rated on a 0-100 scale. Higher scores indicate greater symptom severity. Secondary outcomes include change in GADS-R score from pre-treatment (baseline) to post-treatment, as well as repeated GADS-R assessments administered during treatment (prior to each therapy session) and at 3-month and 12-month follow-up, to monitor clinical change over time.

    Time frame: Pre-treatment (baseline; one week before treatment start) , one day before each therapy session session, post-treatment (one week after last therapy session), 3-month follow-up, 12-month follow-up.

  3. Work and Social Adjustment Scale (WSAS)

    The Work and Social Adjustment Scale (WSAS) is a 5-item self-report questionnaire assessing functional impairment in work, home management, social leisure, private leisure, and close relationships. Scores range from 0-40, with higher scores indicating greater impairment. Secondary outcomes include change in WSAS score from pre-treatment (baseline) to post-treatment (one week after the last therapy session), as well as WSAS scores at 3-month and 12-month follow-up.

    Time frame: Pre-treatment (baseline; one week before treatment start) post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up

  4. Metacognitions Questionnaire- 30 (MCQ-30)

    The Metacognitions Questionnaire- 30 (MCQ-30) is a 30-item self-report measure assessing maladaptive metacognitive beliefs across five domains.Total scores range from 30 to 120, with higher scores indicating stronger dysfunctional metacognitive beliefs.

    Time frame: Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up

  5. Client Satisfaction Questionnaire (CSQ-8)

    The Client Satisfaction Questionnaire (CSQ-8) is an 8-item self-report measure assessing satisfaction with treatment. Total scores range from 8 to 32, with higher scores indicating greater satisfaction.

    Time frame: Post-treatment (one week after the last therapy session)

  6. Working Alliance Inventory - Short, Client Version (WAI-C-S)

    The Working Alliance Inventory - Short, Client Version (WAI-C-S) is a 12-item validated measure assessing the therapeutic alliance across goals, tasks, and bond. Total scores range from 12 to 84, with higher scores indicating a stronger therapeutic alliance.

    Time frame: Mid-treatment A (the day after therapy session 4), mid-treatment B (the day after therapy session 7), and post-treatment (one week after the last therapy session).

  7. EQ-5D-5L

    The EQ-5D-5L is a standardized self-report measure assessing health-related quality of life across five domains and includes a visual analogue scale (VAS). Higher scores indicate better perceived health.

    Time frame: Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up.

  8. Social Phobia Inventory (SPIN)

    The Social Phobia Inventory (SPIN) is a 17-item measure evaluating fear, avoidance, and physiological symptoms of social anxiety. Scores range from 0-68, with higher scores indicating greater social anxiety.

    Time frame: Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up

  9. Work Ability Score (WAS)

    The Work Ability Score (WAS) is a single-item measure rating current work ability compared to lifetime best on a scale of 0-10. Higher scores reflect better work ability.

    Time frame: Pre-treatment (baseline; one week before treatment start), post-treatment (one week after the last therapy session), 3-month follow-up, and 12-month follow-up

  10. Clinical Severity Rating (CSR)

    The Clinical Severity Rating (CSR) is a clinician-rated measure of overall diagnostic severity on a 0-8 scale, where higher scores indicate greater symptom severity and functional impairment. An external, independent clinician (physician or psychologist not involved in treatment or study procedures) conducts a brief structured assessment with each participant. The CSR evaluates both the primary diagnosis of generalized anxiety disorder (GAD) and any comorbid conditions, providing a standardized, observer-based measure of clinical severity and change over time.

    Time frame: Pre-treatment (baseline; one week before treatment start), post-treatment (1 week after the last therapy session), 12-month follow-up.

07

Study locations

2 of 2 sites recruiting
  • Sørlandet Hospital HF
    Kristiansand, Agder, Norway
    Recruiting
  • Sørlandet Hospital HF
    Kristiansand, Norway
    Recruiting
08

References and documents

Publications

  • Brown TA, Barlow DH: Anxiety and related disorders interview schedule for DSM-5 (ADIS-5)-adult and lifetime version: Clinician manual, Oxford University Press; 2014
  • Lundin A, Leijon O, Vaez M, Hallgren M, Torgen M. Predictive validity of the Work Ability Index and its individual items in the general population. Scand J Public Health. 2017 Jun;45(4):350-356. doi: 10.1177/1403494817702759. Epub 2017 Apr 7. PubMed 28385066 ↗
  • Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry. 2000 Apr;176:379-86. doi: 10.1192/bjp.176.4.379. PubMed 10827888 ↗
  • Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727-36. doi: 10.1007/s11136-011-9903-x. Epub 2011 Apr 9. PubMed 21479777 ↗
  • Larsen DL, Attkisson CC, Hargreaves WA, Nguyen TD. Assessment of client/patient satisfaction: development of a general scale. Eval Program Plann. 1979;2(3):197-207. doi: 10.1016/0149-7189(79)90094-6. No abstract available. PubMed 10245370 ↗
  • Wells A, Cartwright-Hatton S. A short form of the metacognitions questionnaire: properties of the MCQ-30. Behav Res Ther. 2004 Apr;42(4):385-96. doi: 10.1016/S0005-7967(03)00147-5. PubMed 14998733 ↗
  • Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002 May;180:461-4. doi: 10.1192/bjp.180.5.461. PubMed 11983645 ↗
  • Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. doi: 10.1016/0005-7967(90)90135-6. PubMed 2076086 ↗
  • Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PubMed 16717171 ↗
  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. PubMed 11556941 ↗

Individual participant data

Plan to share: No — Our ethical approval from the Regional Committees for Medical and Health Research Ethics (REK) does not allow us to share individual participant data (IPD). In accordance with the conditions set by REK, all data are stored securely and cannot be made available to external researchers. Data sharing is further restricted by Norwegian privacy legislation (GDPR) and institutional data protection requirements.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2028, 27 months after the start.

Of 176 non-industry interventional studies with no phase under Generalized Anxiety Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 27 months is close to that.

Counting every sponsor, half of 185 studies reached it within 28 months; a quarter within 15 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
May 12, 2026
StartActual
Mar 27, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07579897
Lead sponsor
Sorlandet Hospital HF
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Mar 27, 2026
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
May 12, 2026

Study contacts

Gunvor Launes, MD Phd
Contact
Gunvor.Launes@sshf.no
+4747661428
Anna Sorte Grindvik, MD
Contact
Anna.Sorte.Grindvik@sshf.no
+4797771807
Gunvor Launes, MD, PhD
principal investigator · Sørlandet Hospital HF

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion